Treatment Outcomes of Intracranial Myeloid Sarcomas: A Meta-Analysis

Dennis Lee, Oluwaseun A. Omofoye, Miriam A. Nuño, Robert A. Riestenberg, Kiarash Shahlaie

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Objective: Intracranial myeloid sarcomas (IMS) are rare central nervous system manifestations of malignant hematopoietic neoplasms of myeloid origin such as acute myeloid leukemia and chronic myeloid leukemia. Reported cases in the literature are limited to primarily case reports. We present a systematic review of this rare central nervous system tumor, characterizing the clinical presentation, tumor location, histopathology, and available treatment modalities. We correlate these variables with mortality, recurrence, and complications to suggest optimal management strategies for IMS. Methods: A systematic literature search was performed across Ovid MEDLINE, Scopus, and Embase using 14 search terms in accordance to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. This systematic review examines variables such as patient age, tumor location, size, presenting symptoms, treatment modality, extent of resection, and mortality. We performed descriptive analyses to identify bivariate associations between patient characteristics, treatment, and outcomes. Results: The mean age at diagnosis was 34.8 years, and the most common etiology was acute myeloid leukemia (68.8%). The most common presenting symptoms were headache (45.5%), vision complaints (27.3%), and weakness/motor symptoms (21.2%). IMS were most commonly located in the temporal lobe (10.1%), cerebellum (10.1%), or falcine/parasagittal (10.1%) region. Patients who received radiotherapy (P < 0.001) or chemotherapy (P < 0.001) had lower rates of mortality versus those who did not. Surgical treatment and extent of resection were not significantly associated with mortality (P > 0.05). Conclusion: The use of adjuvant radiotherapy or chemotherapy for IMS significantly reduces mortality, confirming IMS as a cranial manifestation of a systemic disease. Although surgical treatment is indicated for histopathologic diagnosis and to relieve mass effect, the extent of resection does not predict overall survival.

Original languageEnglish (US)
Pages (from-to)29-37
Number of pages9
JournalWorld Neurosurgery
StatePublished - Apr 2021


  • Acute myelogenous leukemia
  • Chloroma
  • Chronic myeloid leukemia
  • Granulocytic sarcoma
  • Intracranial
  • Leukemia
  • Meta-analysis
  • Myeloid sarcoma

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology


Dive into the research topics of 'Treatment Outcomes of Intracranial Myeloid Sarcomas: A Meta-Analysis'. Together they form a unique fingerprint.

Cite this